BeOne Medicines Ltd. - Sponsored ADR (ONC)
(Delayed Data from NSDQ)
$298.52 USD
-8.71 (-2.84%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $298.88 +0.36 (0.12%) 4:56 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Fundamental Charts
About Return on Equity (TTM)
BeOne Medicines Ltd. - Sponsored ADR 's return on equity, or ROE, is -7.55% compared to the ROE of the Medical - Drugs industry of -57.32%. While this shows that ONC has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
ONC 298.52 -8.71(-2.84%)
Will ONC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ONC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ONC
BeOne Medicines Ltd. - Sponsored ADR (ONC) Reports Q2 Earnings: What Key Metrics Have to Say
Stevanato (STVN) Soars 10.0%: Is Further Upside Left in the Stock?
ONC: What are Zacks experts saying now?
Zacks Private Portfolio Services
BeOne Medicines Ltd. - Sponsored ADR (ONC) Surges 4.0%: Is This an Indication of Further Gains?
Compared to Estimates, BeiGene (ONC) Q1 Earnings: A Look at Key Metrics
Community Health Q1 Earnings Top on Rising Patient Volumes, Stock Up 8%
Other News for ONC
BeOne Medicines Ltd. 2025 Q2 - Results - Earnings Call Presentation
BeOne Medicines Ltd. (ONC) Q2 2025 Earnings Call Transcript
BeOne Medicines outlines $5B–$5.3B 2025 revenue target as BRUKINSA leads BTK market and global expansion accelerates
BeOne Medicines beats top-line and bottom-line estimates; updates FY guidance
ONC Reports Q2 Revenue Surpassing Expectations, Reinforcing Growth Trajectory